The urgent necessity for early disease diagnosis and detection continues to drive innovation in imaging techniques and contrast agents. Nanoparticle-based bioimaging offers significant potential to enhance therapeutics, treatment management, and cancer diagnostics. In both clinical practice and biomedical research, nanoparticles (NPs) can serve as labeled carriers or biomarkers for tracking immunotherapy responses, contrast-enhancing agents for improved imaging, or signal amplifiers to increase specificity and sensitivity in the visualization of cellular and molecular mechanisms in vivo.
The development of advanced imaging probes with controlled biodistribution, heightened sensitivity, improved contrast, multifunctionality, and enhanced temporal and spatial resolution is made possible by the unique chemical, magnetic, and optical properties of nanomaterials. These probes are particularly beneficial, to multi-modal imaging techniques such as single-photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI), and ultrasound (US). Finally, these characteristics contribute to clinical benefits, including personalized medicine, real-time monitoring of disease progression, AI-based design of nanoparticles (NPs) and earlier detection, addressing current limitations in oncologic imaging.